An aging population, an ever increasing amount of time viewing digital devices and a growing trend in eye diseases are all factors expected to fuel a global…


Merck halts Alzheimer’s phase 3 after interim data analysis

Lundbeck calls time on Alzheimer’s drug after more failures

Lilly to ax 200 R&D positions globally

AbbVie hoping for early data readout for anti-tau Alzheimer's drug

Lundbeck inks deal for BBB-crossing shark antibody assets

Akili, Pfizer successfully gamify Alzheimer's

After phase 3 failures, Lilly signs new Alzheimer’s drug pact with AstraZeneca

Analysts on amyloid thesis: It's not dead yet

Alzheimer's hopes dashed as Lilly gives up on amyloid drug solanezumab